CC
ABMD

Chase Coleman’s Abiomed Inc ABMD Stock Holding History

Chase Coleman’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,690,000
Closed -$42M – 67
2014
Q3 		$42M Hold
1,690,000
– – 0.56% 31
2014
Q2 		$42.5M Buy
+1,690,000
New +$39.3M 0.54% 31

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Chase Coleman's ABMD Position: Q4 2014 in Review

Chase Coleman sold out of Abiomed Inc (ABMD) in Q4 2014, closing a stake of 1,690,000 shares — an estimated $42M sold.

Chase Coleman first reported a position in ABMD in Q2 2014 and held it in 2 quarters. The position peaked at $42.5M in Q2 2014. 158 funds tracked by Wall St. Rank hold ABMD as of Q4 2014.

  • Chase Coleman reported no remaining Abiomed Inc position as of Q4 2014 after selling out during the quarter.
  • Chase Coleman sold 1,690,000 Abiomed Inc shares in Q4 2014, an estimated $42M.
  • Chase Coleman first reported a position in Abiomed Inc in Q2 2014 and held it in 2 quarters.
  • Chase Coleman's Abiomed Inc position peaked at $42.5M in Q2 2014.
  • 158 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2014.

Based on Tiger Global Management's 13F filing for Q4 2014, filed 17 Feb 2015.